This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
Cell Death & Disease Open Access 02 December 2020
-
LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1
Molecular Cancer Open Access 22 August 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Creutzig U, Ritter J, Budde M, Sutor A, Schellong G . Early death due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Assoc Hyperleukocytosis Acute Monocytic Leuk Cancer 1987; 60: 3071–3079.
Riley LC, Hann IM, Wheatley K, Stevens RF . Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukaemia Trial (MRC AML10). Br J Haematol 1999; 106: 436–444.
Creutzig U, Zimmermann M, Reinhardt D, Lehrnbecher T . Analyse der Ursachen von Todesfällen im Verlauf der intensiven Anfangschemotherapie in der Studie AML-BFM 93. Klin Pädiatr 2003; 215: 151–158.
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T . Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393.
Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC et al. Death during induction therapy and first remission of acute leukemia in childhood. The St Jude experience. Cancer 2004; 101: 1677–1684.
Slats AM, Egeler RM, van der Does-van den Berg A, Korbijn C, Hahlen K, Kamps WA et al. Cause of death – other than progressive leukemia – in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005; 19: 537–544.
Chan LL, Abdel-Latif ME, Ariffin WA, Ariffin H, Lin HP . Treating childhood acute myeloid leukaemia with tha AML-BFM-83 protocol: experience in a developing country. Br J Haematol 2004; 126: 799–805.
Creutzig U, Ritter J, Schellong G, for the AML-BFM Study Group. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990; 75: 1032–1940.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Quintana, J., Advis, P., Becker, A. et al. Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results. Leukemia 19, 2143–2146 (2005). https://doi.org/10.1038/sj.leu.2403959
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403959
This article is cited by
-
Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML)
Cell Death & Disease (2020)
-
Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country
Annals of Hematology (2019)
-
LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1
Molecular Cancer (2018)
-
Improved treatment results for childhood acute myeloid leukemia in Taiwan
Leukemia (2006)